FORT WORTH, Texas, Jan. 19 (OTC Bulletin Board: WNDM) Wound Management Technologies, Inc., a rapidly growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations was highlighted as part of a presentation exhibited at the SuperBones East conference in Nassau, Bahamas, on January 14-17. The SuperBones Conference has a great reputation for high quality educational lectures and workshops and places top national speakers at the podium. It was designed to provide a specialty education format that includes vital industry topics and techniques to medical practitioners that specialize in treatment of the lower extremities.
Advertisement
The program included a session entitled "Wound Care for the 21st century" during which one of the speakers, Gary Rothenberg, DPM, CDE, CWS, Director of Resident Training and Attending Podiatrist for the Miami Veterans Administration Healthcare System, highlighted CellerateRX as an effective tool in the management of his patients' complicated diabetic ulcers. His presentation, "Emerging Use of Topical Biologicals: in Limb Salvage: The multimodality Treatment Approach" discussed the role of collagen and its significance in wound healing and highlighted successful case use of CellerateRx. "We are doing an IRB study using CellerateRx in our facility. We have seen excellent success when treating the most complicated wounds among our veterans. It is a product that I have found to be cost and clinically effective. I look forward to seeing the outcomes from our randomized control trial." stated Dr. Rothenberg.
Advertisement
Cathy Bradshaw, President of Wound Care Innovations, was quoted as saying "As noted in Dr. Rothenberg's presentation, 85% of all LEA (lower extremity amputations) are preceded by non-healing ulcerations. Our product has been shown to successfully address these diabetic wounds."
"We were delighted to once again be a part of this conference, and it was exciting for us to see CellerateRX recognized during the presentations," continued Bradshaw "Lower extremity wounds and the incidence of amputations is a serious issue in healthcare and we have a product that has been shown to provide quality outcomes in a cost effective manner."
WNDM also announced the completion of sales training for another group of HIRA (Health Industry Representatives Association) reps who will market and sell CellerateRX throughout the United States. "HIRA brings an additional avenue for market penetration for us throughout the United States," added Bradshaw. "Our product successfully addresses a complex and costly segment of healthcare."
CellerateRX® is FDA cleared for acute and chronic wounds which include but are not limited to: diabetic ulcers, venous stasis ulcers, ulcers due to arterial insufficiency, pressure ulcers stages I-IV, surgical wounds, traumatic wounds, superficial wounds, and 1st and 2nd degree burns. It is manufactured in the United States.
For Wound Management Technologies Shareholder Information please call 954-357-0614 or go to http://www.woundmanagementtechnologies.com
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene http://www.celgene.com, Geron http://www.geron.com, and Human Genome Sciences http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit http://www.woundmanagementtechnologies.com
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Product Information Shareholder Relations Cathy Bradshaw Lucy Singleton President Secretary 954-315-9242 817-820-7080
SOURCE Wound Management Technologies, Inc.
